HOOKIPA Pharma, a clinical-stage biopharmaceutical company, reported a net loss of $81.6 million for the year ended December 31, 2023, compared to a net loss of $64.9 million for the previous year. The company's accumulated deficit reached $369.3 million as of December 31, 2023. Despite the losses, HOOKIPA Pharma highlighted progress in its oncology and infectious disease pipelines. The HB-200 program, targeting HPV16+ head and neck cancers, showed a 42% objective response rate in a Phase 2 trial, and preparations for a Phase 2/3 trial are underway. The HB-700 program, in partnership with Roche, is set for an IND submission in Q2 2024, although Roche has terminated the collaboration agreement, effective April 25, 2024. HOOKIPA's infectious disease efforts include the HB-400 program for Hepatitis B and the HB-500 program for HIV, both...Show More

HOOKIPA Pharma, a clinical-stage biopharmaceutical company, reported a net loss of $81.6 million for the year ended December 31, 2023, compared to a net loss of $64.9 million for the previous year. The company's accumulated deficit reached $369.3 million as of December 31, 2023. Despite the losses, HOOKIPA Pharma highlighted progress in its oncology and infectious disease pipelines. The HB-200 program, targeting HPV16+ head and neck cancers, showed a 42% objective response rate in a Phase 2 trial, and preparations for a Phase 2/3 trial are underway. The HB-700 program, in partnership with Roche, is set for an IND submission in Q2 2024, although Roche has terminated the collaboration agreement, effective April 25, 2024. HOOKIPA's infectious disease efforts include the HB-400 program for Hepatitis B and the HB-500 program for HIV, both in partnership with Gilead Sciences. The company plans to focus on advancing its HB-200 program and the Gilead-partnered infectious disease programs. HOOKIPA Pharma has funded operations through public offerings, private placements, and collaboration agreements but does not anticipate positive cash flows from operations in the foreseeable future. The company expects to continue incurring net operating losses and will need substantial additional capital to support its activities.